⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14265648 | 0.83 | — | — | |
| SCHEMBL22930634 | 0.83 | — | — | |
| SCHEMBL24511707 | 0.79 | CYP2C9 (0.34) | — | |
| SCHEMBL28151923 | 0.77 | — | — | |
| SCHEMBL7297483 | 0.75 | — | — | |
| SCHEMBL307642 | 0.75 | — | — | |
| SCHEMBL9686278 | 0.73 | MEN1 (0.37) | — | |
| SCHEMBL14720776 | 0.73 | — | — | |
| SCHEMBL5949386 | 0.73 | — | — | |
| SCHEMBL69189 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4656629-A1 | INDOLE DERIVATIVE WITH SUBSTITUENT AND PHARMACEUTICAL USE | MitoImmune Therapeutics Inc. (KR) | 2025-12-03 | — | — | EP | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-3782994-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| JP-2009022162-A | METHOD FOR PRODUCING TRANS-4-AMINO-1-METHYLCYCLOHEXANOLS | DAICEL CHEM IND LTD | 2009-02-05 | — | — | JP | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070203114-A1 | 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines | ALTANA PHARMA AG (DE) | 2007-08-30 | — | — | US | disclosed |
| US-7179800-B2 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179800-B2 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-15 | — | — | US | disclosed |